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Abstract. Most current anticancer drugs have shown
excellent therapeutic effects on human oral squamous cell
carcinoma (OSCC), but they also produce potent cytotoxicity
in normal oral keratinocytes. This review article summarizes
our extensive research of tumor specificity and keratinocyte
toxicity of nine groups of compounds synthesized in our
laboratory. Among a total of 133 compounds, (E)-3-[2-(4-
hydroxyphenyl)ethenyl]-6-methoxy-4H-1-benzopyran-4-one
[3] (classified as 3-styrylchromones), (E)-3-[2-(4-
chlorophenyl)ethenyl]-7-methoxy-2H-1-benzopyran [4]
(classified as 3-styryl-2H-chromenes) showed the highest
tumor specificity with the least keratinocyte toxicity.
Compound [3] induced apoptotic cell death in a human OSCC
cell line, possibly by down-regulating the glycerophospholipid
pathway. Quantitative structure−activity relationship analysis
demonstrated that the tumor specificities of [3] and [4] were
well correlated with chemical descriptors related to their
molecular size and lipophilicity. Chemical modification of
these lead compounds by introduction of appropriate
functional groups is a crucial step towards manufacturing new
types of anticancer drugs with reduced keratinocyte toxicity. 
Previous studies have focused on the mechanism of
apoptosis induction by anticancer drugs rather than the
demonstration of their tumor specificity. Most anticancer
drugs induce similar morphological changes to those
observed during the developmental process (eliminating
unnecessary tissues and harmful cells).  
Problems of Current Anticancer Drugs
It is well known that administration of anticancer agents
induces skin toxicity (1-7). This prompted us to re-evaluate
the cytotoxicity and tumor specificity of anticancer drugs. For
this purpose, we established an in vitro assay system, using
four human oral squamous cell carcinoma (OSCC) cell lines
(Ca9-22, HSC-2, HSC-3 and HSC-4), three human
mesenchymal normal oral cells [gingival fibroblasts (HGFs),
pulp cells (HPCs), periodontal ligament fibroblasts (HPLFs)]
and two human epithelial normal oral cells [buccal mucosal
human oral keratinocytes (HOKs) and primary human
gingival epithelial cells (HGEPs)] (Figure 1). Cells were
incubated for 48 h with increasing concentrations of test
agents, and the relative viable cell number was determined by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
method. Tumor-selectivity index (TS) was determined by
dividing the mean of the concentration that reduced the viable
cell number by 50% (CC50) of each agent against normal
cells by its mean CC50 against tumor cells (Figure 2A). 
We first investigated the tumor specificity of anticancer
drugs using OSCC cell lines and normal mesenchymal cells
(MCs) (referred to as System 1). Many anticancer drugs, such
as docetaxel, 5-fluorouracil (5-FU), methotrexate, mitomicin
C, etoposide, daunorubicin, doxorubicin, SN-38 (active
metabolite of irinotecan), camptothecin and gefitinib, showed
excellent specificity (TS=10-1000) (Figure 2B) (8). This
validated the present method for evaluating anticancer activity.
We next evaluated the tumor specificity of anticancer
drugs using OSCC cell lines and normal epithelial cells
(ECs.) (referred to as System 2). In this case, anticancer
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agents showed cytotoxicity to both of these cell types to
comparable extents, producing a much lower TS value (9).
It was unexpected that doxorubicin would induce apoptosis
[loss of cell surface microvilli, chromatin condensation,
nuclear fragmentation (Figure 3A) and caspase-3 activation
(Figure 3B)] in HOKs (9). It is therefore imperative to
explore new anticancer drugs with less keratinocyte toxicity. 
In Search of Antitumor Agents with Less 
Toxicity to Keratinocytes
We have synthesized a total of 133 compounds, which are
classified into nine groups, by introducing various functional
groups into distinct backbone structures (Figure 4). The most
potent compound in each group was: (2E)-3-(3,4-dihydroxy-
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Figure 1. Cells used for calculation of CC50 and tumor specificity (TS) value of previously investigated compounds.
Figure 2. A: Exemplary calculation of tumor specificity (TS) value using the concentration that reduced the viable cell number by 50% (CC50)
values for tumor and normal cells. B: Comparison of TS values for antitumor agents and various natural and synthetic compounds. Data are cited
from reference (8).
phenyl)-N-[2-(4-hydroxyphenyl)ethyl]-2-propena-mide [1]
(among 12 phenylpropanoid amides) (10), (2E,4E)-N-[2-(3,4-
dihydroxyphenyl)ethyl]-5-(3,4-methylenedioxyphenyl)-2,4-
pentadienamide [2] (among 12 piperic acid amides) (11), (E)-
3-[2-(4-hydroxyphenyl)ethenyl]-6-methoxy-4H-1-benzopyran-
4-one [3] (among 15 3-styrylchromones) (12, 13), (E)-3-[2-(4-
chlorophenyl)ethenyl]-7-methoxy-2H-1-benzopyran [4] (among
16 3-styryl-2H-chromenes) (14), (Z)-N-[2-(3,4-dihydroxy-
phenyl)ethyl]-9-octadecenamide [5] (among 18 oleoylamides)
(15), (3E)-2,3-dihydro-3-[(3,4-dihydroxyphenyl)methylene]-7-
methoxy-4H-1-benzopyran-4-one [6] (among 17 3-benzyli-
denechromanones) (16), (2E)-1-(2,4-dimethoxyphenyl)-3-(4-
methoxyphenyl)-2-propen-1-one [7] (among 15 chalcones) (17),
(2E,4E)-5-(3,4-methylenedioxyphenyl)-2,4-pentadienoic acid
(4-methoxyphenyl)methyl ester [8] (among 11 piperic acid
esters) (18) and (2Z)-2-[(4-hydroxyphenyl)methylene]-3(2H)-
benzofuranone [9] (among 17 aurones) (19).
Among these nine compounds, [3] and [4] had the highest
TS values (69.0 and 59.9, respectively), as assessed with
System I [OSCC vs. MCs]. Their TS values (59.9-69.0) were
comparable with that of doxorubicin (63.7±95.0) and 5-FU
(13.1±21.1), but greatly exceeded that of resveratrol
(TS=2.4), a stilbene with anticancer activity (20) (Figure 4). 
Compounds [3] and [4] also had the highest TS values when
assessed with System II (OSCC vs. ECs: 204.5 and >85.1,
respectively) (Figure 4). Their TS values were much higher than
those of doxorubicin (1.7±1.9) and 5-FU (1.4±1.1) (Figure 4).
Treatment of HSC-2 cells with [4] induced mitochondrial
vacuolization and inhibition of autophagy (as evidenced by loss
of microtubule-associated protein 1A/1B-light chain 3 (LC3)-
II at an early stage, followed by the induction of apoptosis (as
evidenced by cleavage of poly (ADP-ribose) polymerase and
caspase-3). Compound [4] increased the intracellular levels of
diethanolamine and cytidine diphosphate-choline, whereas it
reduced the level of choline, suggesting down-regulation of the
glycerophospholipid pathway (13).
Estimation of TS by Chemical Descriptors
Six descriptors that correspond greatly with cytotoxicity against
normal cells (N) and tumor cells (T), and with tumor specificity
(T−N) of nine groups of compounds are listed in Table I.
Generally, these descriptors did not overlap with each other.
Tumor specificity of 3-styrylchromones was well corrected with
molecular size (12). T−N can be estimated by molecular
diameter (largest value in the distance matrix defined by the
elements Dij), vsurf_DD23 (interaction with hydrophobic probe
assumed surrounding the molecule) and R3 OH (4’-hydroxy
substitution in the phenyl group of styryl moiety) as:
T−N=0.607(±0.169)diameter – 0.121 (±0.035)vsurf_DD23 +
1.11 (±0.235)R3OH – 7.17 (±2.26), with n=15, R2=0.764,
Q2=0.570. s=0.308 (Figure 5A).
Tumor selectivity of 3-styryl-2H-chromenes correlated well
with six descriptors (std_dim3, BCUT_SLOGP_1, vsurf_D4,
vsurf_R, vsurf_D5 and E_oop) which reflect structure
connectivity and conformation, hydrophobicity, surface rugosity
and out-of-plane potential energy (Table I). The T−N value of
[4] can be estimated using two descriptors (vsurf_R and E_oop)
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Figure 3. Keratinocyte toxicity induced by doxorubicin (DXR). HSC-2
cells were incubated for 0 or 24 h with 10 μM doxorubicin (A), or with
different concentrations of doxorubicin (B), and then processed for
observation under transmission electron microscopy (A) or subjected to
western blot analysis (B). Cited from (9) with permission. PARP: Poly
(ADP-ribose) polymerase; GAPDH: glyceraldehyde 3-phosphate
dehydrogenase.
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Table I. Chemical descriptors that correlate with 50% cytotoxic concentration (CC50) against OSCC (T), normal oral cells (N) and tumor specificity
(T−N) of previously investigated compounds.
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Figure 4. Nine groups of compounds synthesized by chemical modification of back-bone structures present in naturally occurring compounds. OSCC:
Oral squamous cell carcinoma; TS: tumor specificity; MC: mesenchymal cells; EC: epithelial cells.
Figure 5. Multiple regression models for the estimation of the difference in cytotoxicity between tumor and normal cells (T−N) of 3-styrylchromones
(A) and 3-styryl-2H-chromenes (B). Data are cited from references (12) and (14).
as: T−N=32.1(±4.39)vsurf_R + 121(±17)E_oop – 46.1(±6.2),
with n=16, R2=0.870, Q2=0.821, s=0.145 (Figure 5B).
Future Directions
In our work, we have demonstrated that [3] and [4] are two
new compounds that showed the highest TS and potency-
selectivity expression values among the compounds tested, and
they exhibited much less keratinocyte toxicity compared to
doxorubicin and 5-FU (Figure 4). Chemical modification of
these lead compounds by introduction of appropriate functional
groups is a crucial step towards manufacturing new types of
anticancer drugs with reduced keratinocyte toxicity. 
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